Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.
PharmaMar moves ahead with NDA for Zepsyre
Latest NewsThe FDA has given the go-ahead to PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.
Innovative analytical methods for particulate characterization
Sponsored PublicationsManufacturers respond to stricter regulations with novel approaches.
Swedish researchers find new pain organ
Latest NewsResearchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.
Researchers unravel potential cancer target
Latest NewsBritish researchers have found out what’s going wrong with chromosome segregation in some cancers.
Pharming licenses orphan drug from Novartis
Latest NewsNew stem cell population may help repair teeth
Latest NewsResearchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.
Bayer bags iPSC specialist BlueRock Therapeutics
Latest NewsBayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.
Liquid biopsy identifies residual breast cancer
Latest NewsUsing a platform tailored to patients’ specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.
Immunic appoints Sanjay S. Patel as CFO
AppointmentsImmunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.
Novo Holdings puts $72m in Lanzatech
Latest News